ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

AbbVie announced the European Commission (EC) granted marketing authorization for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRa) positive, ...

AbbVie’s monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) has bagged full approval from the US Food and Drug Administration (FDA) for the treatment of certain types of ovarian cancer.

The European Commission (EC) has granted marketing authorisation to AbbVie’s Elahere (mirvetuximab soravtansine) for the treatment of folate receptor-alpha (FRα) platinum-resistant ovarian ...

Specifically, Elahere (mirvetuximab soravtansine) can be used in adults with platinum-resistant, FRα-expressing high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer ...